The unintended burden of increased prostate cancer detection associated with prostate cancer screening and diagnosis.
暂无分享,去创建一个
[1] R A Stephenson,et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. , 2000, Journal of the National Cancer Institute.
[2] A. Evans,et al. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. , 2007, Contemporary clinical trials.
[3] F. Hamdy,et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. , 2008, The Lancet. Oncology.
[4] S. Bloch,et al. Psychological adjustment of men with prostate cancer: a review of the literature , 2007, BioPsychoSocial medicine.
[5] D. Penson,et al. Cross‐sectional and longitudinal comparisons of health‐related quality of life between patients with prostate carcinoma and matched controls , 2004, Cancer.
[6] Brian J. Miles,et al. A Decision Analysis for Treatment of Clinically Localized Prostate Cancer , 1997 .
[7] D. Penson. Quality of Life After Therapy for Localized Prostate Cancer , 2007, Cancer journal.
[8] S. Arver,et al. Waning sexual function--the most important disease-specific distress for patients with prostate cancer. , 1996, British Journal of Cancer.
[9] Peter H Gann,et al. Prostate specific antigen best practice statement: 2009 update. , 2009, The Journal of urology.
[10] D. Radice,et al. Quality of Life and Economic Considerations in the Management of Prostate Cancer , 2012, PharmacoEconomics.
[11] D. Meltzer,et al. The role of anxiety in prostate carcinoma , 2005, Cancer.
[12] Ian M Thompson,et al. Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker , 2004, Cancer.
[13] M. Barry,et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. , 1993, JAMA.
[14] PSA testing: public policy or private penchant? , 2006, JAMA.
[15] J. Manson,et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. , 2009, JAMA.
[16] B. G. Blijenberg,et al. Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.
[17] D. Tindall,et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. , 2004, The Journal of urology.
[18] S. Ramsey,et al. Why do men choose one treatment over another? , 2006, Cancer.
[19] Michael M Lieber,et al. Journal Review , 2003, International Society of Hair Restoration Surgery.
[20] Pascal Pommier,et al. Brachytherapy versus prostatectomy in localized prostate cancer: results of a French multicenter prospective medico-economic study. , 2007, International journal of radiation oncology, biology, physics.
[21] M. Issa,et al. An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. , 2006, The American journal of managed care.
[22] E. Berthelet,et al. Prospective evaluation of the prevalence and severity of fatigue in patients with prostate cancer undergoing radical external beam radiotherapy and neoadjuvant hormone therapy. , 2006, The Canadian journal of urology.
[23] I. Thompson,et al. Finasteride Does Not Increase the Risk of High-Grade Prostate Cancer: A Bias-Adjusted Modeling Approach , 2008, Cancer Prevention Research.
[24] B. Weber,et al. Urinary, sexual, and bowel dysfunction and bother after radical prostatectomy. , 2007, Urologic nursing.
[25] R. Weichselbaum,et al. Potency preservation following conformal radiotherapy for localized prostate cancer: impact of neoadjuvant androgen blockade, treatment technique, and patient-related factors. , 1999, The cancer journal from Scientific American.
[26] David C. Smith,et al. Living with prostate cancer: patients' and spouses' psychosocial status and quality of life. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] David Chia,et al. Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.
[28] F. Hamdy,et al. Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. , 2006, The Journal of urology.
[29] Thomas Wheeler,et al. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. , 2004, The Journal of urology.
[30] R. A. Robinson,et al. Patients' perceptions of quality of life after treatment for early prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Matthew R Cooperberg,et al. Contemporary trends in low risk prostate cancer: risk assessment and treatment. , 2007, The Journal of urology.
[32] Donald E Bailey,et al. Active surveillance for early‐stage prostate cancer , 2008, Cancer.
[33] L. Gomella. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality‐of‐life issues , 2007, BJU international.
[34] I. Thompson. Chemoprevention of prostate cancer: agents and study designs. , 2007, The Journal of urology.
[35] D. Theodorescu,et al. Determinants of long‐term quality of life and voiding function of patients treated with radical prostatectomy or permanent brachytherapy for prostate cancer , 2004, BJU international.
[37] Quality of life and emotional distress in advanced prostate cancer survivors undergoing chemotherapy , 2004, Health and quality of life outcomes.
[38] J. Ware,et al. Health-related quality of life among patients with metastatic prostate cancer. , 1997, Urology.
[39] Andrew J. Vickers,et al. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring , 2008, Nature Reviews Cancer.
[40] J. Gohagan,et al. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. , 2005, Journal of the National Cancer Institute.
[41] E. Giovannucci,et al. The association of treatment‐related symptoms with quality‐of‐life outcomes for localized prostate carcinoma patients , 2002, Cancer.
[42] J. Gore,et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early‐stage prostate cancer , 2007, Cancer.
[43] D. Lubeck,et al. Quality of life before death for men with prostate cancer: results from the CaPSURE database. , 2001, The Journal of urology.
[44] H. D. de Koning,et al. Prostate cancer diagnosis: the impact on patients' mental health. , 2006, European journal of cancer.
[45] V. Moyer,et al. Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.
[46] Susan T. Stewart,et al. Utilities For Prostate Cancer Health States in Men Aged 60 and Older , 2005, Medical care.
[47] P. Stone,et al. A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[48] J. Crowley,et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). , 2009, JAMA.